Bacterial vaccines offer a promising solution by targeting specific pathogens without harming the broader microbiome. However, researchers wrote on August 30, 2024, that developing effective bacterial vaccines is challenging due to the weak immunogenicity of major bacterial antigens.
This emerging antibacterial nanovaccine delivers enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria.
Read More
